HOME >> BIOLOGY >> NEWS
Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune ,,disease and cancer

FREMONT, CALIF., December 1, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has signed a research license and option agreement with Chiron, Inc. ("Chiron") (Nasdaq: CHIR) under which Chiron will use Abgenix's XenoMouse™ technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of autoimmune diseases. In return, Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales by Chiron. Under a separate research collaboration agreement, Chiron may use XenoMouse to generate fully human monoclonal antibodies on up to four cancer targets. Chiron will be responsible for product development, manufacturing, and marketing of any products developed through the collaboration.

"We are delighted to be working with Chiron, one of the world's leading biotechnology companies," stated R. Scott Greer, president and CEO of Abgenix. "Chiron becomes the fourteenth partner using our XenoMouse technology to generate antibody product candidates. This deal also represents the eighth new potential product candidate being pursued by one of our XenoMouse collaborators this year."

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease and cancer. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials.


'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
5. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Chiron reports on discovery of novel men B vaccine candidates based on whole genome sequencing of Neisseria meningitidis by TIGR
8. Chiron Discovers Significant Hepatitis C Binding Mechanism; Data Indicates CD81 Protein May Be A Virus Receptor
9. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
10. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
11. New Arizona State center brings science to policy on issues of water resources and urban growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... FREDERICK, Md. (PRWEB) , ... July 30, 2020 ... ... Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & ... goal of this project is to develop, optimize, and scale-up a highly efficient ...
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a critical ... discover a COVID cure or vaccine, the global economic downturn will only increase price ... not going away and capturing full value from every product launch is critical. However, ...
(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... , ... June 30, 2020 ... ... tissue data insights, today announced that the launch of a new ... with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... develop a vaccine or drug treatment. In an effort to better understand the ... released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 ...
(Date:6/28/2020)... SILVER SPRING, Md. (PRWEB) , ... June 26, ... ... the leading trade association representing security solutions providers, today announced its strong opposition ... . , The bill would impose a blanket ban on most federal use ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... complex indoor environments, announced today that Derek Fournier has been appointed CEO and ... of the Board, effective immediately. , “DeCurtis Corporation has been on an ...
Breaking Biology Technology:
Cached News: